A controlled clinical trial of Dorzolamide: A single-centre subset of a multicentre study

Australian and New Zealand Journal of Ophthalmology

Volumn 24, Issue 1, 1996, Pages 39-42

  Simpson, Allan J ^a   Gray, Trevor B ^a   Ballantyne, Claire ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

dorzolamide; glaucoma; ocular hypertension; topical carbonic anhydrase inhibitor

Indexed keywords

BETAXOLOL; DORZOLAMIDE; TIMOLOL;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMPARISON; HUMAN; INTRAOCULAR HYPERTENSION; OPEN ANGLE GLAUCOMA; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0029891955     PISSN: 08149763     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-9071.1996.tb01549.x     Document Type: Article

References (4)

1. Lippa EA, Carlson LE, Ehinger B, et al. Dose response and duration of action of Dorzolamide, a topical carbonic anhydrase inhibitor. Arch Ophthalmol 1992;110:495-9.
2. Lippa EA, Schuman JS, Higginbotham EJ, et al. MK-507 versus Sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology 1991;98:308-12.
3. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of Dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993;111:1343-50.
4. Smith B, Tipping RW, Lippa E, and The Multicenter Glaucoma Study Group. MRL clinical study report, multicenter study: one-year masked safety and efficacy study of MK-507 ophthalmic solution with Timolol and Betaxolol ophthalmic solutions as positive controls (protocol 025), presented at the ARVO meeting, Sarasota, 1994.